Absence of AKT1 mutations in glioblastoma

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Bleeker, Fonnet E ^a,b   Lamba, Simona ^b   Zanon, Carlo ^b   van Tilborg, Angela A ^c   Leenstra, Sieger ^c,d   Troost, Dirk ^a   Hulsebos, Theo ^a   Vandertop, W Peter ^a,e   Bardelli, Alberto ^b,f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF TURIN   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d CPRLab   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ADULT; ARTICLE; ASTROCYTOMA; CANCER CELL CULTURE; CANCER GRADING; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MUTATIONAL ANALYSIS; SOMATIC MUTATION; ENZYMOLOGY; GENETICS; MIDDLE AGED; MUTATION;

MUS;

FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 66249107937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005638     Document Type: Article

References (22)

1. Brugge J, Hung MC, Mills GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer cell 12: 104-107.
2. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
3. Knobbe CB, Trampe-Kieslich A, Reifenberger G (2005) Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol 31: 486-90.
4. Kita D, Yonekawa Y, Weller M, Ohgaki H (2007) PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol 113: 295-302.
5. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
6. Hartmann C, Bartels G, Gehlhaar C, Holtkamp N, von Deimling A (2005) PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol 109: 639-642.
7. Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, et al. (2008) PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 29: 284-288.
8. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
9. Saal LH, Holm K, Maurer M, Memeo L, Su T, et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
10. Stephens LR, Hughes KT, Irvine RF (1991) Pathway of phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophils. Nature 351: 33-39.
11. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378.
12. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, et al. (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3: e485.
13. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-44.
14. Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, et al. (2007) Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung. Cell Cycle 7: 665-9.
15. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, et al. (2008) AKT1(E17K) in human solid tumours. Oncogene 27: 5648-5650.
16. Kim MS, Jeong EG, Yoo NJ, Lee SH (2008) Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98: 1533-1535.
17. Schuller U, Ruiter M, Herms J, Kretzschmar HA, Grasbon-Frodl E (2008) Absence of mutations in the AKT1 oncogene in glioblastomas and medulloblastomas. Acta Neuropathol 115: 367-368.
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
19. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, et al. (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526.
20. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science 321: 1807-12.
21. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, et al. (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7-11.
22. Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, et al. (2007) Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 67: 3545-3550.